FRLN Freeline Therapeutics Holdings plc

FDA Catalyst Company
0.76
+0.02  (+3%)
Previous Close 0.74
Open 0.78
52 Week Low 0.65
52 Week High 15.4
Market Cap $49,192,775
Shares 64,727,335
Float 64,727,335
Enterprise Value $-4,786,499
Volume 6,998
Av. Daily Volume 240,061
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/01/2022
Redburn Partners Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/07/2022
BTIG Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/29/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/18/2021
JP Morgan Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 08/17/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/19/2021
Guggenheim Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/06/2021
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 04/06/2021
Mizuho Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/23/2021
Stifel Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/02/2021

Latest News

  1. Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones

    Recent appointment of new Chief Financial Officer further strengthens leadership team

    LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today reported financial results for the first quarter of 2022 and provided a business update.

    "We continue the transformation of Freeline to unlock its untapped value, focusing on executing our clinical programs with urgency, demonstrating financial discipline and operational excellence in our business and developing our new R&D strategy to explore the application of our science and platform technologies to new disease areas…

    View Full Article
  2. LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today announced the upcoming presentation of five posters at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that will take place May 16-19, 2022 in Washington, D.C.

    The presentations will provide new insights and data regarding key elements to further enhance the efficacy, safety, sustainability and predictability of adeno-associated virus (AAV)-based gene therapy candidates to treat and potentially cure debilitating genetic disorders, including the following:

    • the development of novel AAV capsid variants with enhanced transduction of liver cells and reduced immunogenicity;
    • the improved assessment…
    View Full Article
  3. LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today announced that Paul M. Schneider has been appointed Chief Financial Officer (CFO), effective May 16, 2022, based in Boston. Mr. Schneider joins Freeline from Exo Therapeutics, Inc., where he served as Senior Vice President, Finance and Operations.

    A seasoned financial executive with more than 20 years of leadership experience in large and small private and public biopharmaceutical companies, Mr. Schneider brings an impressive track record of financial stewardship, including corporate strategy and execution, financial planning, analysis and reporting, and investor relations, to Freeline.

    "I am thrilled to welcome…

    View Full Article
  4. Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease

    Extended financial runway and streamlined organization support Company
    through key data readouts across all three clinical programs

    Strengthened leadership team with appointment of Chief Medical Officer
    and recent addition of Chief Scientific Officer

    LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today reported financial results for the full year 2021 and provided a business update.

    "2022 is shaping up to be a watershed year for Freeline, building on the strong foundation we put in place in the second half of last year," said Michael Parini, Chief Executive Officer of…

    View Full Article
  5. Company to progress to second dose cohort in the MARVEL-1 study immediately,

    with first patient dosing expected in mid-2022

    LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline"), today announced an updated clinical development plan and timelines for FLT190 for people with Fabry disease, a rare, inherited lysosomal storage disorder resulting in cell abnormalities and organ dysfunction that affect small blood vessels, tissues and organs including skin, kidneys, heart, and the nervous system. The Company will proceed immediately to the second dose cohort (1.5e12 vg/kg) in the MARVEL-1 dose escalation study, with the first patient expected to be dosed in mid-2022.

    View Full Article
View All Freeline Therapeutics Holdings plc News